History
2024: Acquisition of a portion of assets by Gedeon Richter
Gedeon Richter announced the completion of negotiations with Mithra Pharmaceuticals SA to acquire part of the company's assets, as well as its Belgian subsidiary Mithra Recherche et Développement SA (Mithra R&D). The transaction involves the purchase of a 100% stake in Estetra SRL ("Aesetra") and Neuralis SA ("Neuralis"), as well as certain assets and licenses of Mithra R & D. The value of the transaction is estimated at 175 million euros, including inherited debt in net terms. Gedeon Richter announced this on June 17, 2024.
The main asset of Mithra is its own development based on aesetrol (E4), a native estrogen. The transaction seeks to acquire exclusive rights to this molecule for various indications and several methods of its synthesis, including an international license for combined and potential products. The purchase includes intellectual property rights, current contracts, as well as obligations related to the ESTELLE drug already on the market and DONESTA drug awaiting registration.
All employees of Neuralis and Estetra retain their jobs after the completion of the transaction. In addition, Mithra employees were also encouraged to join Estetra.
As of June 2024, the transaction was completed and advance payments were made to creditors Mithra Pharmaceuticals SA and Estetra SRL. In doing so, the transaction takes into account contingencies that may affect part of the transaction value.
The acquired assets will give Gedeon Richter the opportunity to further expand its presence in the women's health drugs market, including in the United States, Japan and other countries. The contraceptive drug is already being commercialized, and studies conducted in Liege are aimed at expanding the indications of aesthrol in other promising areas of use for women's health drugs, such as menopause and fertility. The deal is Gedeon Richter's first step towards building its own original research base in women's health - from conducting clinical trials to bringing drugs to market and selling on all continents.
Шаблон:Quote 'author = said Gabor Orban, CEO of Gedeon Richter.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |